AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2022

Sep 7, 2022

31100_dirs_2022-09-07_cbb179cd-60a1-4edb-a9b0-2f8df28bb703.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2022-09-02

Reporting Person: Wassil Jim (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-02	Common Stock	F	2162	$26.38	Disposed	42344	Direct

Footnotes

F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.